At a glance
- Originator Eli Lilly
- Mechanism of Action Somatotropin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Somatotropin deficiency
Most Recent Events
- 15 Sep 1999 Preclinical development for Somatotropin deficiency in USA (Unknown route)